Opposite Expression Patterns of *Spry3* and *p75NTR* in Cerebellar Vermis Suggest a Male-Specific Mechanism of Autism Pathogenesis

Zhenfei Ning, John M. Williams, Romika Kumari[†], Pavel V. Baranov and Tom Moore*

School of Biochemistry and Cell Biology, University College Cork, Cork, Ireland

Autism is a genetically complex neurobehavioral disorder with a population prevalence of more than 1%. Cerebellar abnormalities, including Purkinje cell deficits in the vermis, are consistently reported, and rodent models of cerebellar dysfunction exhibit features analogous to human autism. We previously analyzed the regulation and expression of the pseudoautosomal region 2 gene *SPRY3*, which is adjacent to X chromosome-linked *TMLHE*, a known autism susceptibility gene. *SPRY3* is a regulator of branching morphogenesis and is strongly expressed in Purkinje cells. We previously showed that mouse *Spry3* is not expressed in cerebellar vermis lobules VI–VII and X, regions which exhibit significant Purkinje cell loss or abnormalities in autism. However, these lobules have relatively high expression of *p75NTR*, which encodes a neurotrophin receptor implicated in autism. We propose a mechanism whereby inappropriate *SPRY3* expression in these lobules could interact with TrkB and p75NTR signaling pathways resulting in Purkinje cell pathology. We report preliminary characterization of X and Y chromosome-linked regulatory sequences upstream of *SPRY3*, which are polymorphic in the general population. We suggest that an OREG-annotated region on chromosome Yq12 ~60 kb from *SPRY3* acts as a silencer of Y-linked *SPRY3* expression. Deletion of a β-satellite repeat, or alterations in chromatin structure in this region due to *trans*-acting factors, could affect the proposed silencing function, leading to reactivation and inappropriate expression of Y-linked *SPRY3*. This proposed male-specific mechanism could contribute to the male bias in autism prevalence.

Keywords: autism, cerebellum, *SPRY3*, *p75NTR*, pseudoautosomal region, *TMLHE*, carnitine

INTRODUCTION

Autism is a spectrum disorder whose core features include language delay, social deficits, and restricted interests and repetitive behaviours. In addition, there are significant co-morbidities including attention deficit hyperactivity disorder (ADHD), anxiety, intellectual disability, motor delay, and epilepsy, among others (1–3). Recently, the ESSENCE protocol was developed in response to the increasing diagnosis of autism associated with an expanding list of co-morbidities, including cases in which the co-morbidity may be the predominant clinical entity (1, 4). There is also a trend towards the increased diagnosis and inclusion of cases at the mild end of the spectrum (5). The combined effects of these trends may explain the current estimates of autism prevalence in school

age children, exemplified by two recent reports, which found 1.68% prevalence in the USA and 2.85% in Northern Ireland (6, 7).

Heritability estimates for autism are high, ranging from 38% (8) to more than 80% (9, 10), and there is an emerging consensus that the majority of the genetic risk is attributable to common genetic variants of small effect size acting in combination with rare or *de novo* variants of larger effect size (11–15).

A striking and unexplained feature of autism is the preponderance of affected males, with a sex ratio of between 3 and 4 to 1 consistently reported, including in recent large studies (6, 7, 16, 17). Earlier studies often reported more extreme male biases, particularly in milder cases (so-called high functioning autism or Asperger's syndrome), and there is continuing debate on the possibility of a female protective or "camouflage" effect that may result in their under-diagnosis (18–25). Currently, multiple genes and genomic variants are associated with autism with varying levels of confidence; however, the majority are autosomal and do not explain observed sex differences in prevalence (26). Rather than exhibiting sex-specific expression, autism genes may interact with normal regulatory pathways that are themselves sex-specifically regulated (27–29). This is conceptually similar to the proposal that autism genes operate against a background of sex-specific hormone profiles (30–32), and shifts the explanatory burden from the autism genes themselves to the normal sex-specific pathways with which they interact.

We previously analyzed the pseudoautosomal region 2 (PAR2)-linked *SPRY3* gene in autism because it is highly expressed in the cerebellum (33), a region consistently implicated in autism pathogenesis (34–39). *SPRY3* is expressed in Purkinje cells, a key cell type deficient in autism (40, 41), but we note that mouse *Spry3* is not expressed in the cerebellar lobules (VI–VII, X) homologous to those most affected in human autism (33, 41). If this expression pattern is recapitulated in the human, as suggested by a human *SPRY3* promoter–LacZ transgenic mouse strain (33), it suggests two alternative mechanisms by which *SPRY3* could be implicated in loss of Purkinje cells preferentially in these lobules. First, the normal absence of *SPRY3* expression in these lobules may increase their sensitivity to genetic or environmental "insults" that cause Purkinje cell loss. However, this would not explain the male bias. Second, the deregulation and inappropriate overexpression of *SPRY3* in these lobules may be pathogenic, and could provide a male-specific mechanism, as described below. SPRY3 is a receptor tyrosine kinase (RTK) signaling inhibitor that interacts with the TrkB neurotrophin receptor pathway (42), which is implicated in autism and social behavior (43–49).

The X-linked copy of *SPRY3* is adjacent to a known autism gene, *TMLHE*, and a proportion of *SPRY3* transcripts arise from upstream promoters in the X-linked *F8A3* and *TMLHE* regions (33). The *F8A2–F8A3* region contains an inversion polymorphism that could potentially affect the expression of flanking genes, including *SPRY3*. The Y-linked copy of *SPRY3* is epigenetically silenced in normal males (50), which could contribute to the male bias in autism due to X-linkage of the expressed gene copy. Alternatively, deregulation and reactivation of the silenced Y-linked copy could provide a male-specific

pathological mechanism. A possible further mode of *SPRY3* deregulation is suggested by the fact that *SPRY3* is upregulated in the liver of piglets fed high levels of carnitine (51). Notably, the gene adjacent to *SPRY3*, *TMLHE*, encodes an enzyme in the carnitine biosynthesis pathway. As carnitine deficiency is implicated in autism causation (52), this suggests a mechanism whereby carnitine levels could impact on *SPRY3* regulation and autism.

In this study, we examined the expression of *SPRY3* and its functionally associated genes in cerebellum, and we analyzed genetic variation in predicted X and Y chromosome regulatory regions that may impact on *SPRY3* expression. We propose a pathogenic mechanism in autism involving *SPRY3* deregulation impacting on the BDNF–TrkB–p75NTR neurotrophin pathway.

MATERIALS AND METHODS

Online Bioinformatics and Other Resources

The following databases and online resources were used in this study: UCSC genome browser (https://genome.ucsc.edu/); GENSAT Brain Atlas of gene expression in EGFP Transgenic Mice (http://gensat.org/index.html); Allen Brain Atlases (http://portal.brain-map.org/; 53); GTEx Portal, v7, updated 09/05/2017 (https://gtexportal.org/home/); SFARI (Simon Foundation Autism Research Initiative; https://www.sfari.org/); AGRE (Autism genetic Resource Exchange; https://research.agre.org/program/descr.cfm). Other websites are listed under "Analysis of PsychENCODE data."

Whole Mount Immunohistochemistry of Mouse Cerebellum

All reagents were from Sigma, UK, unless otherwise stated. Adult male and female C57Bl/6J mice were humanely euthanized under permissions obtained following animal ethics and welfare review by UCC committees, under national and European legislation. Dissected mouse cerebellum was fixed in 4% Paraformaldehyde (PFA)-Phosphate-buffered saline (PBS) for 10 h, post-fixed in methanol–Dimethyl sulfoxide (DMSO) (4:1) overnight at 4ºC, and then bleached in methanol–DMSO–30% H_2O_2 (4:1:1) overnight at 4ºC. After 3 × 60 min wash in 100% methanol, it was frozen at −80ºC and thawed at room temperature (RT) for six cycles in 100% methanol. After rehydrating with 50% methanol, 15% methanol, and PBS for 2 h each, it was digested by proteinase K (10 mg/ml; Sigma, UK) in PBS for 3 min at RT, washed in PBS for 3 × 2 h at RT, and incubated in PBS with 10% goat serum and 0.1% Triton X-100 overnight at 4ºC. It was then incubated with anti-Spry3 primary antibody (Abcam, UK) in PBS containing 10% goat serum, 0.1% Triton X-100, 5% DMSO for 48 h at 4ºC and washed twice in PBS containing 10% goat serum, 0.1% Triton X-100 for 20 min each, followed by incubation with secondary antibody in PBS containing 10% goat serum, 0.1% Triton X-100, 5% DMSO for 24 h at 4ºC. It was then washed twice in PBS containing 10% goat serum, 0.1% Triton X-100 for 2 h each. Immunoreactivity was visualized by incubating the

cerebellum in freshly prepared DAB solution (Sigma, UK) for 3 min at RT. The stained cerebellum was imaged with a Nikon SMZ1500 microscope and Nikon DXM1200 camera.

Droplet Polymerase Chain Reaction Analysis of *F8A2–F8A3* Inversion Genotype

All reagents were from Sigma, UK, unless otherwise stated. Cultured cells were lysed in lysis buffer (0.1 M Tris, 0.2 M NaCl, 5 mM EDTA, 0.4% SDS, and 0.2 mg/ml proteinase K, pH 8.0) at 55ºC. Cell DNA was precipitated by adding isopropanol and washed with 70% ethanol. DNA pellet was dissolved in water and digested with *Nru*I and *Bsp*EI (NEB, UK). Polymerase chain reactions (PCRs) were prepared in a total volume of 100 μl with 1× Go-taq buffer (Promega, UK), 25 mM MgCl$_2$, 250 μM dNTPs, 1 μM primers (Eurofins Genomics, Germany): F8A2-F1-2 5′-CAC ATGATGAAAGTGGGAGGA-3′, F8A2-R2-2 5′-GAATGCAACA AATCAGCAAGA-3′, and F8A2-R3-2 5′-TTCAGACCCATATAG TATTACTGGTGA-3′, 30 nM primer F8A2-R1-2 5′-GCATACAC TGCTAGGTGGGAATTCACAGCCACTGGAATGAC-3′, 200 ng digested genomic DNA, and 16 units Go-Taq DNA polymerase.

Emulsion step was carried out by adding PCR reaction dropwise over 30 s to 200 μl light mineral oil with 4.5% v/v Span 80, 0.4% v/v Tween 80, and 0.05% Triton X-100, in a 2 ml Corning Cryo-Tube stirring with a magnetic bar (8 × 3 mm with a pivot ring; VWR) at 1,000 rpm. Emulsions were stirred for 3 min before being overlaid with 30 μl mineral oil. The PCR conditions were 95°C for 120 s; 40 cycles of 95°C for 20 s, 60°C for 30 s, and 72°C for 15 s; 72°C for 5 min. Emulsions were disrupted using 600 μl hexane. Each clean PCR product (2 μl) was amplified in a total volume of 50 μl using primers F8A2-F1-2, F8A2-R2-2, and F8A2-R3-2 and reaction mix: 1× Go-taq buffer, 5 μl 25 mM MgCl$_2$, 250 μM dNTPs, 300 nM primers, and 1 unit Go-Taq DNA polymerase.

Lymphoblastoid Cell Lines and DNA Samples

Cell lines and DNA samples were randomly selected from AGRE (https://research.agre.org/program/descr.cfm) and SFARI (https://www.sfari.org/) resources. AGRE samples are from multiplex families, and SFARI samples are from simplex families. Further details are available from provider websites using sample reference numbers listed below. Additional autism DNA samples were obtained from Prof. David Skuse, University College London. Control DNA samples were from the Caucasian DNA panel from the Coriell Institute for Medical Research, USA. Cells were grown in T25 suspension cell flasks with RPMI-1640 medium supplemented with 10% FBS (Sigma, UK) at 37°C, 5% CO$_2$.

Cell lines used were as follows (double-underlining indicates samples with F8A2–F8A3 inversion; see Results section): AGRE: 2095, 2325, 2396, 2479, 2609, 2615, 2659, 2664, 2718, 2815, 2838, 2853, 2880, 2883, 3126, 2742, 2831, 2327, 2628, 2678, 2326, 2791, 2487, 2328.
SFARI: SSC00317, SSC00591, SSC00636, SSC02727, SSC03440, SSC03459, SSC03537, SSC03774, SSC03989, SSC04232, SSC05124, SSC05350, SSC05435, SSC07444, SSC10172, SSC10210, SSC10777, SSC11067, SSC12271.

Long-Range PCR of β-Satellite Repeat

PCR reactions were prepared in a total volume of 50 μl with 25 μl 2× GoTaq Long PCR Master Mix (Promega, UK), 10 μl 300 nM primers (Eurofins Genomics, Germany) (Y-Chr BSR-Del-3F 5′-CACAGGCTGTAGTGCAGGTGATG-3′ and Y-Chr BSR-Del-4R 5′-CTGTGTTGTTGATCTGTCTAATGTTGACA TTA-3′), and 500 ng genomic DNA. The PCR conditions were 95°C for 120 s; 40 cycles of 93°C for 20 s, 60°C for 16 min; final extension of 72°C for 20 min.

Analysis of PsychENCODE Data

We obtained paired-end RNA-seq libraries of cerebellar vermis from 33 autism and 38 controls from PsychENCODE (54). Individual libraries contained 50–200 million reads. Human transcriptome sequence was obtained from the RefSeq database (55), downloaded from NCBI (Annotation Release 108). Raw reads were aligned to the set of human RefSeq transcript sequences using bowtie2 short read alignment program (56). Default parameters were used for local alignments. Reads mapping to only one location in the transcriptome were selected by removing the alignments with "XS:i" bowtie2 tag, which represents reads having more than one possible mapping to the reference. SAMtools version 1.3.1 (57) was used to obtain the sorted BAM alignment files, which were further used to predict the heterozygosity in *SPRY3* expressed sequences. *SPRY3* had a total mapped read count range of 653–4033. SAMtools mpileup (57) and BCFtools (58) were used to characterize variations in mapped reads at each coordinate in the *SPRY3* locus. The frequency of variants at each position was analyzed to estimate the likelihood of heterozygosity. For heterozygous genotypes, it is expected that the probability of finding a nucleotide matching the reference sequence at the single nucleotide polymorphism (SNP) position is 0.5, while for homozygous genotypes it is either 0 or 1.

RESULTS

Cerebellar Lobule Gene Expression Screen Identifies Opposite Expression of *Spry3* and *p75NTR* in Lobules VI–VII and X

We used whole mount immunohistochemistry of cerebellums from adult male and female C57Bl/6J strain mice and confirmed relatively low Spry3 expression in lobules VI–VII and X, as previously noted in mouse Allen Brain Atlas (ABA) and GENSAT data [**Figure 1A**, **B**, **F**; see also Ref. (33)]. We next sought to determine whether other genes share this expression pattern by visually inspecting the spatial expression patterns of genes in sagittal sections of the mouse ABA data as follows: i) 54 genes with biased expression in "Cerebellar cortex, Purkinje layer" under the "Fine Structure Search" option of the mouse ABA (**Supplementary Table 1**); ii) mouse homologues of 87 high-risk autism genes from SFARI (https://www.sfari.org/resource/sfari-gene/#bottom; **Supplementary Table 2**). Three of 54 cerebellar cortex-biased gene set (*Abhd3*, *Lrp8*, and *Plcβ4*) had lower expression in lobules VI–VII and X (**Figure 1G**, **H**, **I**),

FIGURE 1 | Lobular expression of genes in adult mouse cerebellum. **(A, B)** *Spry3*. **(C)** Human *SPRY3* promoter–LacZ reporter transgenic mouse. **(D, E)** *p75NTR*. **(F)** Representative whole mount immumohistochemistry of adult female mouse cerebellum using anti-Spry3 antibody. **(G–I)** *Abhd3*, *Lrp8*, and *Plcβ4*. Images **(A, D)** and **(G–I)** were from Allen Brain Atlas; **(B** and **E)** were from GENSAT. Data for images **(A–C)** were previously published (31) and are included here for comparison with p75NTR expression. Roman numerals (I–X) in panel A indicate lobule identity. Arrowheads indicate lobules VI–VII and X with notable gene expression patterns.

reminiscent of the *Spry3* pattern, but none of 87 SFARI gene mouse homologues had this pattern; however, many of the latter had faint staining and were difficult to score.

Transcription factors (TFs) predicted to regulate human *SPRY3* (ZNF263, MAZ, PURA, EGR1, PAX6) are expressed in mouse Purkinje cells (33), and GTEx data confirm relatively high expression of these factors in human adult cerebellum (**Figure 2**). However, limited data on these genes in ABA and GENSAT did not allow us to determine whether their spatial expression patterns coincide with *Spry3* lobular expression.

We next examined spatial expression of *Spry1*, *Spry2*, and *Spry4*; neurotrophins (*Ngf*, *Bdnf*, *NTF3*, and *NTF4*); neurotrophin receptors (*p75NTR*, *TrkA*, *TrkB*, and *TrkC*); and *Bex3* (*Ngfrap1*), which encodes a p75NTR interacting protein (59), in cerebellum to determine possible lobular co-expression with *Spry3*. On ABA, *Spry1* and *Spry4* exhibit faint staining, whereas *Spry2* is widely expressed, including in cerebellar Purkinje cells, but does not exhibit a specific lobular expression pattern like *Spry3*. This is consistent with GTEx data in which *SPRY2* has relatively high expression in human cerebellum, whereas *SPRY1* and *SPRY4* exhibit no and low expression, respectively (**Figure 2**).

For the neurotrophins, expression data on GTEx indicated that *BDNF* and *NTF3* are relatively highly expressed in cerebellum, compared to other brain regions, whereas there was no expression of *NGF* and *NTF4* (**Figure 2**). However, on ABA, mouse *Ntf4* is expressed in Purkinje cells, whereas there is no *Bdnf* or *Ngf*, and barely detectable *Ntf3* expression. It is unclear if these species differences reflect biological differences or technical limitations.

The data for neurotrophin receptor expression were generally consistent between ABA (mouse) and GTEx (human) datasets. On ABA, *TrkB* is widely expressed in the brain, including in cerebellar Purkinje cells, and GTEx data also indicated its wide expression in brain including cerebellum (**Figure 2**). *TRKA* and *TRKC* exhibited low and moderate expression, respectively, on GTEx, and no expression was detected on ABA. Analysis of *p75NTR* expression in GTEx suggested that it is virtually absent from the central nervous system, apart from a marginal signal in cerebellum and high expression in the peripheral nervous system

FIGURE 2 | GTEx data for genes associated with *SPRY3* expression and regulation. Cerebellum samples are boxed to highlight expression relative to other tissues: brain–cerebellar hemisphere; brain–cerebellum. Note different scales on TPM (transcripts per million) Y-axis for each gene.

(spinal cord, tibial nerve; **Figure 2**). However, scrutiny of ABA and GENSAT data indicated wide expression of *p75NTR* in the mouse adult brain, but with restricted expression in cerebellar vermis Purkinje cells, largely restricted to lobules VI–VII and X (**Figure 1D**, **E**), the exact opposite of the *Spry3* lobular expression pattern. *Bex3* (and other *Bex* genes; data not shown) is expressed throughout the adult mouse brain (ABA), including in cerebellar Purkinje cells, and is highly expressed in human cerebellum (**Figure 2**).

Genetic Analysis of X Chromosome-Linked Regulatory Sequences Upstream of Human *SPRY3*

The unique genomic configuration of human *SPRY3* due to the evolution of the PAR2 in the hominin lineage suggests that sex-linked upstream elements could regulate expression of X-linked *SPRY3* and epigenetic silencing of Y-linked *SPRY3* (33). X-linked *SPRY3* transcription initiates in the *F8A3–TMLHE* region (33). *F8A3* is associated with inversions involving *F8A1* and *F8A2* (60, 61). The *F8A2–F8A3* interval contains regulatory elements approximately 20 and 60 kb centromeric of F8A3 (**Figure 3**). Inversion of this sequence might affect regulation of flanking genes including *F8A3* region-associated *SPRY3* transcription. We developed a single-molecule droplet PCR assay to determine the

orientation of the *F8A2–F8A3* interval using a modified version of Turner et al. (62, 63) (**Figure 4**). We analyzed DNA from autism cases comprising 20 individuals from SFARI resource and 24 individuals from AGRE, representing simplex and multiplex families, respectively (see Materials and Methods for sample identifiers). There were 2/20 and 4/24 inversions compared to the reference sequence (GRCh38/hg38 assembly, December 2013, UCSC browser), which is similar to the 20% frequency (4/20 samples) found in non-autistic *F8* gene-associated hemophilia patients (64).

Analysis of Y Chromosome-Linked Regulatory Sequences Upstream of Human *SPRY3*

We hypothesised that Y chromosome sequences proximal to the Yq–PAR2 boundary act as a silencer of Y-linked *SPRY3*. Scrutiny of this region using the UCSC browser identified a predicted regulatory region that begins 60 kb upstream of the *SPRY3* PAR2 transcriptional start site (TSS) and extends a further 60 kb towards the centromere. This element comprises compositionally distinct regions of ~25 and ~35 kb and is flanked by a 50 kb sequence gap proximally, on the far side of which are the major Yq12 satellite sequences (**Figure 5**). The 25 kb region comprises ~10 kb of simple CATTC and CACTC repeats, while the remaining

FIGURE 3 | ENCODE/OREG annotations in Xq28 F8A2–F8A3 interval.

FIGURE 4 | Strategy for single-molecule PCR genotyping of F8A2–F8A3 inversion polymorphism. Ref, orientation allele described in reference sequence on UCSC browser (HumanGRch37/hg19); Inv, opposite orientation to reference sequence.

FIGURE 5 | ENCODE/OREG annotations in Yq12 and 10q26.3 regions showing major DNA factors binding in BSR regions (ZNF263, EGR1). Note different scales in each panel.

~15 kb is a beta satellite repeat (BSR). The entire ~60 kb region has multiple *DNase*I sensitive sites and CTCF binding sites (data not shown), and the BSR, similarly to the *SPRY3* core promoter AG-rich repeat, contains multiple ZNF263 binding sites. BLAST of the ~15 kb Yq12 BSR identified related sequences on chrs. 4, 10, 14, and 18 with 100% coverage and identity scores of 78–83%. The BSR-containing allele of the *FSHD* gene locus on chr. 4q35 (65) is not represented on the UCSC browser; but the structurally similar 10q26.3 locus is (66, 67). This exhibits a different pattern of chromatin modifications to the Yq12 BSR, increasing our confidence in the attribution of Yq12 annotations (**Figure 5**).

Inspection of the Yq12 region in the database of structural variants (DSV) using the UCSC browser indicated significant variability of the BSR, including independently reported deletions and duplications (**Figure 6A**). We attempted to use

long PCR of genomic DNA using primers flanking the BSR to determine whether structural variants or length polymorphisms are associated with autism. Primer design was severely restricted due to the genomic architecture of the region, and the selected primer pair amplified a ~3.8 kb product from all male samples and no female samples (**Figure 6B**). Samples were as follows: 20 male autism (AGRE); 21 male autism (Skuse samples); 12 normal male and 4 normal female (Skuse and Coriell Caucasian panel). Cloning of this PCR product was problematic, but sequences obtained from both ends of a cloned partial product matched the expected 5′ and 3′ boundaries of the reference sequence (**Figure 6C**). However, this product was not amplified from BAC clone RP11-88F4, which covers the region, reducing confidence in the genomic location of the template for the ~3.8 kb amplicon (data not shown).

FIGURE 6 | (A) Map of genomic variants in Yq12 region. Details of annotated publication references are available on UCSC browser. **(B)** Male-specific ~3.5 kb PCR product amplified by BSR-specific primers (8 of 57 samples analyzed are shown). **(C)** Sequences of 5′ and 3′ ends of cloned PCR product.

Analysis of *SPRY3* Allele-Specific Expression in Cerebellum Using PsychENCODE Dataset

Genetic and structural analysis of the Yq12 putative regulatory region was inconclusive; therefore, we looked for loss of epigenetic silencing and reactivation of the Y-linked *SPRY3* allele in a comparison of RNA-Seq data from male autism and control cerebellum samples. We obtained paired-end RNA-seq libraries of cerebellar vermis from 33 autism and 38 control samples from PsychENCODE (54). Genotypes for X and Y chromosome (including PAR2) markers are not available for these samples; therefore, we used a statistical approach to analyze the level of heterozygosity of transcripts of the *SPRY3* and control genes. Heterozygous expression of *SPRY3* would be indicative of expression of both X- and Y-linked alleles due to pathological reactivation of the Y-linked copy. Genes flanking *SPRY3* were also examined. *TMLHE* was used as a negative control to estimate the level of variants due to technical noise (e.g., sequencing errors, substitutions during library preparation, and misalignments) since it is X-linked and no bona fide heterozygosity is expected. *SYBL1* was analyzed because it flanks *SPRY3* distally and is similar to *SPRY3* in having a Y-linked copy; however, its silencing is associated with a methylated CpG island, and it may be regulated differently to *SPRY3* (68). Autosomal genes (*NPTN* and *MCM6*) were used as positive controls, where we expected to identify heterozygosity. There was no significant difference in the heterozygosity plots of autism versus control samples for any of the genes analyzed (**Figure 7**; **Supplementary Figure 1**).

DISCUSSION

We have extended our previous work implicating *SPRY3* in autism (33) and provide evidence for a possible mechanism of

chromosome Y-linked *SPRY3* gene deregulation underpinning male susceptibility. At the cellular level, we propose that *SPRY3* deregulation affects the functioning of the BDNF–TrkB–p75NTR neurotrophin pathway, leading to cerebellar Purkinje cell pathology. Our hypothesis can explain the specific lobular distribution of Purkinje cell loss in autism (lobules VI, VII, and X), as previously described (41). More speculatively, *SPRY3* deregulation could explain a reported, although currently unconfirmed, lung branching abnormality in autism (69).

The male bias in autism prevalence is not explained by known DNA susceptibility variants because the majority are autosomal, and a major sex-linked gene effect has not been identified (10, 14, 17, 26, 70–76). This suggests that autosomal variants interact with one or more sex-specific developmental or regulatory pathways, which could include sex hormones, or X or Y chromosome-linked gene-encoded regulators. This hypothesis requires that the majority (perhaps hundreds) of individual susceptibility variants converge on sex-specific mechanisms that underpin either a female protective effect or male susceptibility effect (FPE or MSE) (27, 29). The plausibility of FPE/MSE mechanisms is supported by mouse mutants of known autism genes, which exhibit sex-specific phenotypes (77–79), the presence of X-linked regulators expressed differently in males and females (80), and the influence of sex hormones such as testosterone and estrogen on normal and abnormal brain development and function (30, 31, 81–83).

However, recent studies did not detect a predicted Carter effect in autism because an increase in disease aggregation in families with a female proband was not observed, as would be expected if affected females require a higher mutation burden to overcome an FPE threshold (73, 84–86). This suggests that sex-specific departures from normal physiology, rather than normal sex-specific physiology *per se*, may underlie the male bias in autism (87). An alternative hypothesis to FPE/MSE is therefore the existence of one or more male-specific disease mechanisms

FIGURE 7 | Comparison of *SPRY3* (RefSeq ID: NM_005840) expression heterozygosity maps for autism and control samples. SNP positions 4704, 4706, and 4708 (highlighted in red, blue, and green, respectively) produced all possible genotypes in the majority of control and autism samples, suggesting a sequencing artefact at these positions, and were not counted as heterozygotes. Female sample 1412 position is included as indicative of a true heterozygous sample.

FIGURE 8 | Model of regulation of human *SPRY3* by X and Y chromosome-linked regulatory regions and deregulation in autism. We propose that regions including the *F8A2–F8A3* interval and associated transcription spanning the Xq28–PAR2 boundary, and Y-linked ENCODE/OREG-annotated regions including the BSR, may be deregulated by *cis-* or *trans*-acting factors. More specifically, we propose that cis-acting Yq12 genomic variants, including BSR length variants, may result in variable reactivation and expression of Y-linked *SPRY3*, leading to inappropriate lobular expression. Y-linked transcription may have altered lobular expression due to lack of putative Xq28-linked regulatory elements associated with the normal pattern of lobular expression from X-linked *SPRY3* or due to influence of Yq12 genomic elements.

(MDM). Such MDM would have to occur at a high frequency to explain the large male prevalence bias.

There are potentially two general mechanisms of *SPRY3* deregulation in autism. First, *trans*-acting effects of susceptibility variants at other loci encoding, for example, chromatin regulators could deregulate X- or Y-linked *SPRY3*. This category would also include environmental effects, for example, due to alterations in carnitine levels, to which *SPRY3* may be responsive (see below). Second, *cis*-acting *de novo* mutations or common variants in regulatory regions could cause aberrant expression of X- or Y-linked *SPRY3*. Previous genetic studies have not associated the Xq28 or PAR2 regions with autism (88). However, both the X and Y chromosome regions upstream of PAR2 are structurally complex and difficult to analyze, and therefore, autism-associated variants may have been overlooked.

The *F8A2–F8A3* interval has a common inversion polymorphism that may alter the orientation and distance from *SPRY3* of ENCODE/OREG-predicted regulatory sequences. The major regulatory factors that bind in this region (TRIM28, SMARCA4) are associated with autism (89–91); therefore, inversions or other rearrangements of this region may impact on expression of F8A2/F8A3 region-associated transcription or on flanking genes (*CLIC2, TMLHE, SPRY3*), potentially contributing to autism risk. It is unknown how frequently *de novo*

inversions occur, and inversion alleles are not tagged by known SNPs. Therefore, we used single-molecule analysis to determine orientation of this inversion in a small number of autism and control DNA samples. We observed similar allele frequencies to those reported from an analysis of 20 hemophilia patients (64), with no evidence of a strong association with autism.

The Yq12 PAR2 region is poorly characterized due to the absence of genetic recombination and the highly repetitive DNA sequences that comprise much of the Yq and PAR2 boundary regions. However, our identification of a putative regulatory region in distal Yq12, 60 kb upstream of the *SPRY3* TSS, suggests a mechanism of silencing of Y-linked *SPRY3*. Similar to the *SPRY3* core promoter AG-rich repeat (33), a BSR in this region has multiple ZNF263 binding sites, suggesting a possible regulatory interaction with the *SPRY3* promoter. A BSR at chr. 10q26.3, also annotated in ENCODE, has a different pattern of chromatin modifications, increasing confidence in the Yq12 annotations. Interestingly, copy number variants (CNV) in the 10q26.3 region are associated with autism, although there is no evidence that this is due to the BSR (92; https://gene.sfari.org/database/cnv/10q26.3). Non-BSR sequences in the Yq12 region have abundant CTCF binding sites, a factor associated with gene imprinting and genome topology (93), further suggesting a regulatory function for this region in regulating Y-linked *SPRY3*.

There is extensive sequence and structural variation across the Yq12 putative regulatory region, including reported length polymorphisms of the BSR. However, BSRs are abundant in the genome (94, 95), and the majority are not annotated; therefore, caution is required when interpreting annotations arising from genome-wide studies underpinned by short sequence reads. We were unable to confirm Yq12 BSR variation using long PCR due to severe sequence constraints in primer design and instability of cloned PCR products. Other approaches, such as fiber FISH or single-molecule sequencing, anchored in unique sequences in PAR2, will be required to provide confirmation of BSR length alleles and to conduct genetic association studies. We also cannot exclude a role for somatic cell mutations, which are increasingly implicated in neurodegeneration (96). Somatic instability of the repeat-rich Yq12–PAR2 region could result in cell autonomous DNA rearrangements and deregulation of Y-linked *SPRY3*.

Notwithstanding significant technical difficulties in analyzing the Yq12–PAR2 boundary region, our data suggest a hypothetical mechanism whereby genetic (DNA sequence) or epigenetic (chromatin structure) variation could lead to reactivation and inappropriate lobular expression of Y-linked *SPRY3*. We sought to test this hypothesis by analyzing allelic expression of *SPRY3* in PsychENCODE cerebellum expression data, but we did not detect biallelic expression in male samples as would be predicted if the Y-linked copy is active. However, we lacked the sample genotypes and information about the exact cerebellar lobules sampled. Also, the pathological mechanism we propose may not be detectable in RNA-Seq data if reactivation of Y-linked *SPRY3* ultimately results in Purkinje cell death. Therefore, we do not consider this a definitive rejection of our hypothesis.

A possible further mode of *SPRY3* deregulation is suggested by its linkage with *TMLHE* and their overlapping regulatory sequences (33). TMLHE is an enzyme in the carnitine biosynthesis pathway, and carnitine deficiency is associated with autism (52, 97, 98). Intriguingly, there is evidence that carnitine levels modulate *SPRY3* expression in the pig (51). *TMLHE* mutations are rare but well-established autism susceptibility factors (52, 88, 97, 99, 100). Mouse *Tmlhe* is expressed in Purkinje cells; however, the lobular expression pattern is not restricted like *Spry3*. At least one mutation attributed to *TMLHE*-associated autism risk also affects *SPRY3* sequences (33), suggesting a possible role for deregulation of *SPRY3* in some reported cases.

Deficits in cerebellar vermis structure and Purkinje cell number and morphology have been reported frequently in autism at post mortem, using MRI imaging, and in mouse models (39, 82, 101–110). In a histological study of human brain tissues from autism cases, Skefos et al. (41) reported that Purkinje cell loss predominantly affects crus I and II (lobule VIIa), and they also noted a possible male-specific deficit in lobule X of the flocculonodular lobe. Following our previous study (33), and arising from our current observations, we show that mouse *Spry3* and *p75NTR* have opposite expression patterns in cerebellar vermis lobules VI–VII and X. *Spry3* is not expressed in these lobules, whereas *p75NTR* is strongly expressed [see also **Figure 2** in Ref. (111) and **Figure 1F** in Ref. (112)]. In a screen of 135 genes in the adult mouse (selected for high cerebellar expression or prior association with autism), we identified only three (*Abhd3*, *Lrp8*, and *Plcβ4*) with a

somewhat similar lobular expression pattern to *Spry3*, and none that recapitulated the *p75NTR* expression pattern. This suggests that there are relatively few genes whose expression could explain the lobular pattern of abnormalities described by Skefos et al. (41). Our qualitative screen of the ABA mouse data was restricted to adult brain and may therefore lack sensitivity; however, we are reassured regarding its specificity by an independent report that *Plcβ4* is not expressed in lobules VI–VII and IX–X (113).

The opposite expression patterns of *Spry3* and *p75NTR* mirror the well-known opposite expression patterns of *zebrin II/aldolase C* and *Hsp25/Hspb1* on the anterior–posterior (AP) axis (114–118). The mechanisms responsible for patterning the anterior–posterior axis of the cerebellum include the autism gene *Engrailed-2* (*En2*; 118, 119), and intriguingly, *En2* has specific functions in the development of lobules VI–VII and X (118, 120), suggesting a further mechanism underpinning involvement of these lobules in autism (after 39).

A recent report suggests that lobules VI–VII (Crus I) in rodents are homologous to Crus I and II in primates (121). Therefore, if mouse *Spry3* and *p75NTR* expression patterns are conserved in human, as appears likely from a *SPRY3* promoter–reporter transgenic mouse (33), and scrutiny of the ABA (human) and GTEx databases, we can propose an MDM in which aberrant expression of human *SPRY3* in lobules VI–VII and X interferes with neurotrophin signaling, causing Purkinje cell pathology through a BDNF–TrkB–p75NTR mechanism. Spry1, 2, and 4 regulate receptor tyrosine kinase signaling including FGFR (122–125), whereas evidence from *Xenopus* and mouse indicates a regulatory loop involving BDNF- and TrkB-dependent expression of *Spry3*, and Spry3-mediated inhibition of BDNF–TrkB signaling (42). Therefore, it is possible that both SPRY3 and p75NTR proteins interact with BDNF–TrkB signaling, a pathway implicated in neuronal (including Purkinje) cell development and survival (126–130). Although *p75NTR* is not listed on the SFARI autism gene database, it is a compelling candidate for involvement in autism pathogenesis (128, 131, 132). There is extensive evidence of both pro- and anti-apoptotic functions for p75NTR, particularly in contexts with concomitant alteration of neurotrophin receptor signaling, including of TrkB (130, 133–138). SPRY3 regulates TrkB signaling (42); therefore, we speculate that inappropriate expression of SPRY3 in lobules VI–VII and X, in the context of TrkB and p75NTR expression, may affect Purkinje cell function or survival, although the exact mechanism would have to be established in relevant models, as neurotrophin signaling effects depend strongly on physiological context (136, 139).

We previously reported that a human *SPRY3* promoter–LacZ reporter transgenic mouse substantially recapitulated the mouse *Spry3* expression pattern (33). Similar to mouse *Spry3*, human *SPRY3*-LacZ is expressed in Purkinje cells throughout the cerebellum, except in lobules VI–VII. However, unlike mouse *Spry3*, human *SPRY3*-LacZ is expressed in lobule X. Therefore, sequences outside of the human core promoter, or *trans*-acting factors whose expression differs between mouse and human, may be required for regulation of *SPRY3* in this lobule. Interestingly, the deficits in lobule X identified by Skefos et al. (41) may be male-specific, which, in the context of our proposed mechanism of pathological over-expression of *SPRY3*, could indicate a role for deregulation

(reactivation) of the Y-linked copy in this lobule, which might have a different expression pattern compared to the X-linked copy due to the lack of cis-acting X-linked regulatory sequences, or the inappropriate influence of Y-linked sequences (**Figure 8**).

Finally, we note that Sprouty was originally described based on a branching phenotype of the apical airways of Drosophila (140), and mouse *Spry2* coordinates vascular and airway branching in the lung (141). *Spry3* is expressed in the mouse lung bronchial tree (our unpublished data) and in human lung (GTEx), suggesting that deregulation of *SPRY3* could potentially provide a mechanism underpinning a lung branching abnormality reported in autism patients (69).

In future work, we aim to deepen our understanding of *SPRY3* and *p75NTR* expression and functional interactions during brain and lung development in the human and mouse, including in autism mouse models. Transgenic under- or over-expression of *Spry3* in cerebellar lobules VI–VII and X in mice would provide an *in vivo* model of our proposed MDM in autism. Due to the unique genomic architecture and regulation of the human PAR2, and the difficulty in sourcing matched tissue samples from specific cerebellar lobules from normal and autism brains, and from other organs such as lung, the analysis of Y-linked *SPRY3* deregulation in the cerebellum and lung will be challenging, particularly if the pathology results in cell death. However, advances in single-molecule DNA sequencing techniques will facilitate detection of genomic variants in this region that may be associated with autism.

ETHICS STATEMENT

Access to human genetic data and biomaterials for this study was carried out in accordance with the procedures and recommendations of the UCC Office of the Vice-President for Research and Innovation, specifically for accessing AGRE and SFARI datasets and biomaterials, under their respective procedures. All subjects gave written informed consent in accordance with AGRE and SFARI protocols and procedures, consistent with the Declaration of Helsinki. Access to animal tissues for this study was pursued in accordance with the recommendations of the UCC Animal Experimentation and Ethics Committee under licencing from the Irish Health Products Regulatory Authority (https://www.hpra.ie/).

AUTHOR CONTRIBUTIONS

ZN and JW carried out all of the bench work and aspects of bioinformatics and data analysis. RK and PB carried out analysis of PsychENCODE data. TM conceived of, and supervised, the study and wrote most of the manuscript. All authors contributed to various aspects of manuscript preparation.

FUNDING

ACKNOWLEDGMENTS

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2019.00416/full#supplementary-material

SUPPLEMENTARY TABLE 1 | Mouse Purkinje cell expressed genes whose spatial expression was examined in Allen Brain Atlas data. For consistency, the numbering scheme for the 54 genes identified as "cerebellum, Purkinje cell enhanced" in the Allen Brain Atlas "fine structure" search is maintained here, with inclusion of two blank rows (29 and 53).

SUPPLEMENTARY TABLE 2 | Human autism genes from SFARI "High confidence" and "Strong candidate" lists (https://www.sfari.org/resource/sfari-gene/#bottom) for which spatial expression of their mouse orthologues was examined in Allen Brain Atlas data.

SUPPLEMENTARY FIGURE 1 | Comparison of SPRY3 expression heterozygosity map with maps for TMLHE (X-linked), SYBL1 (PAR2-linked), and NPTN, MCM6 (autosomal) genes.

REFERENCES

1. Gillberg C. The ESSENCE in child psychiatry: early symptomatic syndromes eliciting neurodevelopmental clinical examinations. *Res Dev Disabil* (2010) 31:1543–51. doi: 10.1016/j.ridd.2010.06.002
2. Constantino JN, Charman T. Diagnosis of autism spectrum disorder: reconciling the syndrome, its diverse origins, and variation in expression. *Lancet Neurol* (2016) 15(3):279–91. doi: 10.1016/S1474-4422(15)00151-9
3. Posserud M, Hysing M, Helland W, Gillberg C, Lundervold AJ. Autism traits: the importance of "co-morbid" problems for impairment and contact with services. Data from the Bergen Child Study. *Res Dev Disabil* (2018) 72:275–83. doi: 10.1016/j.ridd.2016.01.002
4. Gillberg C, Fernell E. Autism plus versus autism pure. *J Autism Dev Disord* (2014) 44(12):3274–6. doi: 10.1007/s10803-014-2163-1
5. Whitehouse AJ, Cooper MN, Bebbington K, Alvares G, Lin A, Wray J, et al. Evidence of a reduction over time in the behavioral severity of

autistic disorder diagnoses. *Autism Res* (2017) 10(1):179–87. doi: 10.1002/aur.1740

6. Baio J, Wiggins L, Christensen DL, Maenner MJ, Daniels J, Warren Z, et al. Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2014. *MMWR Surveill Summ* (2018) 67(6):1–23. doi: 10.15585/mmwr.ss6706a1

7. Waugh I. The prevalence of autism (including Asperger syndrome) in school age children in Northern Ireland 2017. (2017) https://dera.ioe.ac.uk/29786/1/asd-children-ni-2017_Redacted.pdf.

8. Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, et al. Genetic heritability and shared environmental factors among twin pairs with autism. *Arch Gen Psychiatry* (2011) 68(11):1095–102. doi: 10.1001/archgenpsychiatry.2011.76

9. Tick B, Bolton P, Happé F, Rutter M, Rijsdijk F. Heritability of autism spectrum disorders: a meta-analysis of twin studies. *J Child Psychol Psychiatry* (2016) 57(5):585–95. doi: 10.1111/jcpp.12499

10. Sandin S, Lichtenstein P, Kuja-Halkola R, Hultman C, Larsson H, Reichenberg A. The heritability of autism spectrum disorder. *JAMA* (2017) 318(12):1182–4. doi: 10.1001/jama.2017.12141

11. Casey JP, Magalhaes T, Conroy JM, Regan R, Shah N, Anney R, et al. A novel approach of homozygous haplotype sharing identifies candidate genes in autism spectrum disorder. *Hum Genet* (2012) 131:565–79. doi: 10.1007/s00439-011-1094-6

12. Huguet G, Ey E, Bourgeron T. The genetic landscapes of autism spectrum disorders, *Annu Rev Genom Hum Genet* (2013) 14:191–213. doi: 10.1146/annurev-genom-091212-153431

13. Weiner DJ, Wigdor EM, Ripke S, Walters RK, Kosmicki JA, Grove J, et al. Polygenic transmission disequilibrium confirms that common and rare variation act additively to create risk for autism spectrum disorders. *Nat Genet* (2017) 49(7):978–85. doi: 10.1038/ng.3863

14. Constantino JN. Deconstructing autism: from unitary syndrome to contributory developmental endophenotypes. *Int Rev Psychiatry* (2018) 30(1):18–24. doi: 10.1080/09540261.2018.1433133

15. Bourgeron T. Current knowledge on the genetics of autism and propositions for future research. *C R Biol* (2016) 339(7-8):300–7. doi: 10.1016/j.crvi.2016.05.004

16. Loomes R, Hull L, Mandy WPL. What is the male-to-female ratio in autism spectrum disorder? A systematic review and meta-analysis. *J Am Acad Child Adolesc Psychiatry* (2017) 56(6):466–74. doi: 10.1016/j.jaac.2017.03.013

17. Palmer N, Beam A, Agniel D, Eran A, Manrai A, Spettell C, et al. Association of sex with recurrence of autism spectrum disorder among siblings. *JAMA Pediatr* (2017) 171(11):1107–12. doi: 10.1001/jamapediatrics.2017.2832

18. Scott FJ, Baron-Cohen S, Bolton P, Brayne C. Brief report: prevalence of autism spectrum conditions in children aged 5-11 years in Cambridgeshire, UK. *Autism* (2002) 6(3):231–7. doi: 10.1177/1362361302006003002

19. Baron-Cohen S, Lombardo MV, Auyeung B, Ashwin E, Chakrabarti B, Knickmeyer R. Why are autism spectrum conditions more prevalent in males? *PLoS Biol* (2011) 9(6):e1001081. doi: 10.1371/journal.pbio.1001081

20. Gould J, Ashton-Smith J. Missed diagnosis or misdiagnosis? Girls and women on the autism spectrum. *Good Autism Practice* (2011) 12(1):34–41.

21. Mandy W, Chilvers R, Chowdhury U, Salter G, Seigal A, Skuse D. Sex differences in autism spectrum disorder: evidence from a large sample of children and adolescents. *J Autism Dev Disord* (2012) 42(7):1304–13. doi: 10.1007/s10803-011-1356-0

22. Dworzynski K, Ronald A, Bolton P, Happé F. How different are girls and boys above and below the diagnostic threshold for autism spectrum disorders? *J Am Acad Child Adolesc Psychiatry* (2012) 51(8):788–97. doi: 10.1016/j.jaac.2012.05.018

23. Adviento B, Corbin IL, Widjaja F, Desachy G, Enrique N, Rosser T, et al. Autism traits in the RASopathies. *J Med Genet* (2014) 51(1):10–20. doi: 10.1136/jmedgenet-2013-101951

24. Westman Andersson G, Miniscalco C, Gillberg C. Autism in preschoolers: does individual clinician's first visit diagnosis agree with final comprehensive diagnosis? *Sci World J* (2013) 2013:716267. doi: 10.1155/2013/716267

25. Lai MC, Baron-Cohen S, Buxbaum JD. Understanding autism in the light of sex/gender. *Mol Autism* (2015) 6:24. doi: 10.1186/s13229-015-0021-4

26. Sanders SJ, He X, Willsey AJ, Ercan-Sencicek AG, Samocha KE, Cicek AE, et al. Insights into autism spectrum disorder genomic architecture and biology from 71 risk loci. *Neuron* (2015) 87(6):1215–33. doi: 10.1016/j.neuron.2015.09.016

27. Werling DM, Parikshak NN, Geschwind DH. Gene expression in human brain implicates sexually dimorphic pathways in autism spectrum disorders. *Nat Commun* (2016) 7:10717. doi: 10.1038/ncomms10717

28. Ecker C, Andrews DS, Gudbrandsen CM, Marquand AF, Ginestet CE, Daly E, et al. Association between the probability of autism spectrum disorder and normative sex-related phenotypic diversity in brain structure. *JAMA Psychiatry* (2017) 74(4):329–410. doi: 10.1001/jamapsychiatry.2016.3990

29. Floris DL, Lai MC, Nath T, Milham MP, Di Martino A. Network-specific sex differentiation of intrinsic brain function in males with autism. *Mol Autism* (2018) 9:17. doi: 10.1186/s13229-018-0192-x

30. Baron-Cohen S. The extreme male brain theory of autism. *Trends Cogn Sci* (2002) 6:248–54. doi: 10.1016/S1364-6613(02)01904-6

31. Baron-Cohen S, Auyeung B, Nørgaard-Pedersen B, Hougaard DM, Abdallah MW, Melgaard L, et al. Elevated fetal steroidogenic activity in autism. *Mol Psychiatry* (2014) 20:369–76. doi: 10.1038/mp.2014.48

32. Werling DM. The role of sex-differential biology in risk for autism spectrum disorder. *Biol Sex Differ.* (2016) 7:58. doi: 10.1186/s13293-016-0112-8

33. Ning Z, McLellan AS, Ball M, Wynne F, O'Neill C, Mills W, et al. Regulation of SPRY3 by X chromosome and PAR2-linked promoters in an autism susceptibility region. *Hum Mol Genet* (2015) 24(18):5126–41. Erratum in: Hum Mol Genet. 2015 Dec 20;24(25):7450. doi: 10.1093/hmg/ddv231

34. Becker EB, Stoodley CJ. Autism spectrum disorder and the cerebellum. *Int Rev Neurobiol* (2013) 113:1–34. doi: 10.1016/B978-0-12-418700-9.00001-0

35. Rogers TD, McKimm E, Dickson PE, Goldowitz D, Blaha CD, Mittleman G. Is autism a disease of the cerebellum? An integration of clinical and pre-clinical research. *Front Syst Neurosci* (2013) 7:15. doi: 10.3389/fnsys.2013.00015

36. Jeong J-W, Tiwari VN, Behen ME, Chugani HT, Chugani DC. In vivo detection of reduced Purkinje cell fibers with diffusion MRI tractography in children with autistic spectrum disorders. *Front Hum Neurosci* (2014) 8:110. doi: 10.3389/fnhum.2014.00110

37. Hampson DR, Blatt GJ. Autism spectrum disorders and neuropathology of the cerebellum. *Front Neurosci* (2015) 9:420. doi: 10.3389/fnins.2015.00420

38. Stoodley CJ, D'Mello AM, Ellegood J, Jakkamsetti V, Liu P, Nebel MB, et al. Altered cerebellar connectivity in autism and cerebellar-mediated rescue of autism-related behaviors in mice. *Nat Neuroscience* (2017) 20:1744–51. doi: 10.1038/s41593-017-0004-1

39. Zhao G, Walsh K, Long J, Gui W, Denisova K. Reduced structural complexity of the right cerebellar cortex in male children with autism spectrum disorder. *PLoS One* (2018) 13(7):e0196964. doi: 10.1371/journal.pone.0196964

40. Whitney ER, Kemper TL, Rosens DL, Bauman ML, Blatt GJ. Density of cerebellar basket and stellate cells in autism: evidence for a late developmental loss of Purkinje cells. *J Neurosci Res* (2009) 87:2245–54. doi: 10.1002/jnr.22056

41. Skefos J, Cummings C, Enzer K, Holiday J, Weed K, Levy E, et al. Regional alterations in purkinje cell density in patients with autism. *PLoS One* (2014) 9(2):e81255. doi: 10.1371/journal.pone.0081255

42. Panagiotaki N, Dajas-Bailador F, Amaya E, Papalopulu N, Dorey K. Characterisation of a new regulator of BDNF signalling, Sprouty3, involved in axonal morphogenesis in vivo. *Development* (2010) 137(23):4005–15. doi: 10.1242/dev.053173

43. Correia CT, Coutinho AM, Sequeira AF, Sousa IG, Lourenço Venda L, Almeida JP, et al. Increased BDNF levels and NTRK2 gene association suggest a disruption of BDNF/TrkB signaling in autism. *Genes Brain Behav* (2010) 9(7):841–8. doi: 10.1111/j.1601-183X.2010.00627.x

44. Castrén ML, Castrén E. BDNF in fragile X syndrome. *Neuropharmacology* (2014) 76 Pt C:729–36. doi: 10.1016/j.neuropharm.2013.05.018

45. Koh JY, Lim JS, Byun HR, Yoo MH. Abnormalities in the zinc-metalloprotease-BDNF axis may contribute to megalencephaly and cortical hyperconnectivity in young autism spectrum disorder patients. *Mol Brain* (2014) 7:64. doi: 10.1186/s13041-014-0064-z

46. Zheng Z, Zhang Li, Zhu T, Huang J, Qu Y, Mu D. Peripheral brain-derived neurotrophic factor in autism spectrum disorder: a systematic review and meta-analysis. *Sci Rep* (2016) 6:31241. doi: 10.1038/srep31241

47. Kang MS, Choi TY, Ryu HG, Lee D, Lee SH, Choi SY, et al. Autism-like behavior caused by deletion of vaccinia-related kinase 3 is improved by TrkB stimulation. *J Exp Med* (2017) 214(10):2947–66. doi: 10.1084/jem.20160974

48. Ka M, Kim WY. ANKRD11 associated with intellectual disability and autism regulates dendrite differentiation via the BDNF/TrkB signaling pathway. *Neurobiol Dis* (2018) 111:138–52. doi: 10.1016/j.nbd.2017.12.008

49. Maynard KR, Hobbs JW, Phan BN, Gupta A, Rajpurohit S, Williams C, et al. BDNF-TrkB signaling in oxytocin neurons contributes to maternal behaviour. *eLife.* (2018) 7:e33676. doi: 10.7554/eLife.33676

50. De Bonis ML, Cerase A, Matarazzo MR, Ferraro M, Strazzullo M, Hansen RS, et al. Maintenance of X- and Y-inactivation of the pseudoautosomal (PAR2) gene SPRY3 is independent from DNA methylation and associated to multiple layers of epigenetic modifications. *Hum Mol Genet* (2006) 15:1123–32. doi: 10.1093/hmg/ddl027

51. Keller J, Ringseis R, Priebe S, Guthke R, Kluge H, Eder K. Effect of L-carnitine on the hepatic transcript profile in piglets as animal model. *Nutr Metab (Lond)* (2011) 8:76. doi: 10.1186/1743-7075-8-76

52. Beaudet AL. Brain carnitine deficiency causes nonsyndromic autism with an extreme male bias: a hypothesis. *Bioessays* (2017) 39(8):1–26. doi: 10.1002/bies.201700012

53. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, et al. Genome-wide atlas of gene expression in the adult mouse brain. *Nature* (2007) 445:168–76. doi: 10.1038/nature05453

54. Parikshak NN, Swarup V, Belgard TG, Irimia M, Ramaswami G, Gandal MJ, et al. Genome-wide changes in lncRNA, splicing, and regional gene expression patterns in autism. *Nature* (2016) 540(7633):423–7. Erratum in: Nature. 2018 Aug;560(7718):E30. doi: 10.1038/nature20612

55. O'Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. *Nucleic Acids Res* (2016) 44(D1):D733–45. doi: 10.1093/nar/gkv1189

56. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol* (2009) 10(3):R25. doi: 10.1186/gb-2009-10-3-r25

57. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics.* (2009) 25(16):2078–9. doi: 10.1093/bioinformatics/btp352

58. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, Depristo MA, et al. The variant call format and VCFtools. *Bioinformatics* (2011) 27(15):2156–8. doi: 10.1093/bioinformatics/btr330

59. Cabral KM, Raymundo DP, Silva VS, Sampaio LA, Johanson L, Hill LF, et al. Biophysical studies on BEX3, the p75NTR-associated cell death executor, reveal a high-order oligomer with partially folded regions. *PLoS One* (2015) 10(9):e0137916. doi: 10.1371/journal.pone.0137916

60. El-Hattab AW, Schaaf CP, Fang P, Roeder E, Kimonis VE, Church JA, et al. Clinical characterization of int22h1/int22h2-mediated Xq28 duplication/deletion: new cases and literature review. *BMC Med Genet* (2015) 16:12. doi: 10.1186/s12881-015-0157-2

61. Bagnall RD, Ayres KL, Green PM, Giannelli F. Gene conversion and evolution of Xq28 duplicons involved in recurring inversions causing severe hemophilia A. *Genome Res* (2005) 15(2):214–23. doi: 10.1101/gr.2946205

62. Turner DJ, Shendure J, Porreca G, Church G, Green P, Tyler-Smith C, et al. Assaying chromosomal inversions by single-molecule haplotyping. *Nat Methods* (2006) 3(6):439–45. doi: 10.1038/nmeth881

63. Turner DJ, Hurles ME. High-throughput haplotype determination over long distances by haplotype fusion PCR and ligation haplotyping. *Nat Protoc* (2009) 4(12):1771–83. doi: 10.1038/nprot.2009.184

64. Bagnall RD, Giannelli F, Green PM. Int22h-related inversions causing hemophilia A: a novel insight into their origin and a new more discriminant PCR test for their detection. *J Thromb Haemost* (2006) 4(3):591–8. doi: 10.1111/j.1538-7836.2006.01840.x

65. Kim E, Rich J, Karoutas A, Tarlykov P, Cochet E, Malysheva D, et al. ZNF555 protein binds to transcriptional activator site of 4qA allele and ANT1: potential implication in Facioscapulohumeral dystrophy. *Nucleic Acids Res.* (2015) 43(17):8227–42. doi: 10.1093/nar/gkv721

66. van der Maarel SM, Frants RR. The D4Z4 repeat-mediated pathogenesis of facioscapulohumeral muscular dystrophy. *Am J Hum Genet* (2005) 76(3):375–86. Epub 2005 Jan 24. Review. No abstract available. doi: 10.1086/428361

67. Krom YD, Thijssen PE, Young JM, den Hamer B, Balog J, Yao Z, et al. Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHD. *PLoS Genet* (2013) 9(4):e1003415. doi: 10.1371/journal.pgen.1003415

68. Matarazzo MR, De Bonis ML, Gregory RI, Vacca M, Hansen RS, Mercadante G, et al. Allelic inactivation of the pseudoautosomal gene SYBL1 is controlled by epigenetic mechanisms common to the X and Y chromosomes. *Hum Mol Genet* (2002) 11(25):3191–8. doi: 10.1093/hmg/11.25.3191

69. Stewart BA, Klar AJ. Can bronchoscopic airway anatomy be an indicator of autism? *J Autism Dev Disord* (2013) 43(4):911–6. doi: 10.1007/s10803-012-1635-4

70. Hartley SL, Sikora DM. Sex differences in autism spectrum disorder: an examination of developmental functioning, autistic symptoms, and coexisting behaviour problems in toddlers. *J Autism Dev Disord* (2009) 39(12):1715–22. doi: 10.1007/s10803-009-0810-8

71. Virkud YV, Todd RD, Abbacchi AM, Zhang Y, Constantino JN. Familial aggregation of quantitative autistic traits in multiplex versus simplex autism. *Am J Med Genet B Neuropsychiatr Genet* (2009) 150B(3):328–34. doi: 10.1002/ajmg.b.30810

72. Constantino JN, Zhang Y, Frazier T, Abbacchi AM, Law P. Sibling recurrence and the genetic epidemiology of autism. *Am J Psychiatry* (2010) 167(11):1349–56. doi: 10.1176/appi.ajp.2010.09101470

73. Constantino JN. Data from the Baby Siblings Research Consortium confirm and specify the nature of the female protective effect in autism: a commentary on Messinger et al. *Mol Autism* (2016) 7:32. doi: 10.1186/s13229-016-0092-x

74. Szatmari P, Liu XQ, Goldberg J, Zwaigenbaum L, Paterson AD, Woodbury-Smith M, et al. Sex differences in repetitive stereotyped behaviors in autism: implications for genetic liability. *Am J Med Genet B Neuropsychiatr Genet* (2012) 159B(1):5–12. doi: 10.1002/ajmg.b.31238

75. Robinson EB, Lichtenstein P, Anckarsater H, Happe F, Ronald A. Examining and interpreting the female protective effect against autistic behavior. *Proc Natl Acad Sci U S A* (2013) 110(13):5258–62. doi: 10.1073/pnas.1211070110

76. Gaugler T, Klei L, Sanders SJ, Bodea CA, Goldberg AP, Lee AB, et al. Most genetic risk for autism resides with common variation. *Nat Genet* (2014) 46(8):881–5. doi: 10.1038/ng.3039

77. Binder MS, Lugo JN. NS-Pten knockout mice show sex- and age-specific differences in ultrasonic vocalizations. *Brain Behav* (2017) 7(11):e00857. doi: 10.1002/brb3.857

78. Berkel S, Eltokhi A, Fröhlich H, Porras-Gonzalez D, Rafiullah R, Sprengel R, et al. Sex hormones regulate SHANK expression. *Front Mol Neurosci* (2018) 11:337. doi: 10.3389/fnmol.2018.00337

79. Weinhard L, Neniskyte U, Vadisiute A, di Bartolomei G, Aygün N, Riviere L, et al. Sexual dimorphism of microglia and synapses during mouse postnatal development. *Dev Neurobiol* (2018) 78(6):618–26. doi: 10.1002/dneu.22568

80. Raznahan A, Parikshak NN, Chandran V, Blumenthal JD, Clasen LS, Alexander-Bloch AF, et al. Sex-chromosome dosage effects on gene expression in humans. *Proc Natl Acad Sci U S A* (2018) 115(28):7398–403. doi: 10.1073/pnas.1802889115

81. Hedges VL, Ebner TJ, Meisel RL, Mermelstein PG. The cerebellum as a target for estrogen action. *Front Neuroendocrinol* (2012) 33(4):403–11. doi: 10.1016/j.yfrne.2012.08.005

82. Hoffman JF, Wright CL, McCarthy MM. A critical period in Purkinje cell development is mediated by local estradiol synthesis, disrupted by inflammation, and has enduring consequences only for males. *J Neurosci* (2016) 36(39):10039–49. doi: 10.1523/JNEUROSCI.1262-16.2016

83. Greenberg DM, Warrier V, Allison C, Baron-Cohen S. Testing the empathizing-systemizing theory of sex differences and the extreme male brain theory of autism in half a million people. *Proc Natl Acad Sci U S A* (2018) 115(48):12152–7. doi: 10.1073/pnas.1811032115

84. Carter CO, Evans KA. Inheritance of congenital pyloric stenosis. *J Med Genet* (1969) 6:233–54. doi: 10.1136/jmg.6.3.233

85. Goin-Kochel RP, Abbacchi A, Constantino JN, Autism Genetic Resource Exchange Consortium. Lack of evidence for increased genetic loading for autism among families of affected females: a replication from family history data in two large samples. *Autism* (2007) 11(3):279–86. doi: 10.1177/1362361307076857

86. Messinger D, Young GS, Ozonoff S, Dobkins K, Carter A, Zwaigenbaum L, et al. Beyond autism: a baby siblings research consortium study of high-risk children at three years of age. *J Am Acad Child Adolesc Psychiatry* (2013) 52(3):300–8.e1. doi: 10.1016/j.jaac.2012.12.011

87. Turner TN, Coe BP, Dickel DE, Hoekzema K, Nelson BJ, Zody MC. Genomic patterns of de novo mutation in simplex autism. *Cell* (2017) 171(3):710–22. e12. doi: 10.1016/j.cell.2017.08.047

88. Celestino-Soper PB, Violante S, Crawford EL, Luo R, Lionel AC, Delaby E, et al. A common X-linked inborn error of carnitine biosynthesis may be a risk factor for nondysmorphic autism. *Proc Natl Acad Sci U S A* (2012) 109(21):7974–81. doi: 10.1073/pnas.1120210109

89. Zhang Z, Cao M, Chang CW, Wang C, Shi X, Zhan X, et al. Autism-associated chromatin regulator Brg1/SmarcA4 is required for synapse development and myocyte enhancer factor 2-mediated synapse remodeling. *Mol Cell Biol* (2015) 36(1):70–83. doi: 10.1128/MCB.00534-15

90. Lee N, Park SJ, Haddad G, Kim DK, Park SM, Park SK, et al. Interactomic analysis of REST/NRSF and implications of its functional links with the transcription suppressor TRIM28 during neuronal differentiation. *Sci Rep* (2016) 6:39049. doi: 10.1038/srep39049

91. Watanabe M, Hatakeyama S. TRIM proteins and diseases. *J Biochem* (2017) 161(2):135–44. doi: 10.1093/jb/mvw087

92. Ghasemi Firouzabadi S, Vameghi R, Kariminejad R, Darvish H, Banihashemi S, Firouzkouhi Moghaddam M, et al. Analysis of copy number variations in patients with autism using cytogenetic and MLPA techniques: report of 16p13.1p13.3 and 10q26.3 duplications. *Int J Mol Cell Med* (2016) 5(4):236–45.

93. Ghirlando R, Felsenfeld G. CTCF: making the right connections. *Genes Dev* (2016) 30(8):881–91. doi: 10.1101/gad.277863.116

94. Waye JS, Willard HF. Human beta satellite DNA: genomic organization and sequence definition of a class of highly repetitive tandem DNA. *Proc Natl Acad Sci U S A* (1989) 86(16):6250–4. doi: 10.1073/pnas.86.16.6250

95. Cardone MF, Ballarati L, Ventura M, Rocchi M, Marozzi A, Ginelli E, et al. Evolution of beta satellite DNA sequences: evidence for duplication-mediated repeat amplification and spreading. *Mol Biol Evol* (2004) 21(9):1792–9. doi: 10.1093/molbev/msh190

96. Leija-Salazar M, Piette C, Proukakis C. Somatic mutations in neurodegeneration. *Neuropathol Appl Neurobiol* (2018) 44(3):267–85. doi: 10.1111/nan.12465

97. Ziats MN, Comeaux MS, Yang Y, Scaglia F, Elsea SH, Sun Q, et al. Improvement of regressive autism symptoms in a child with TMLHE deficiency following carnitine supplementation. *Am J Med Genet* (2015) 167A:2162–7. Note: Erratum: Am. J. Med. Genet. 167A: 2496 only. doi: 10.1002/ajmg.a.37144

98. Krsička D, Geryk J, Vlčková M, Havlovicová M, Macek M Jr, Pourová R. Identification of likely associations between cerebral folate deficiency and complex genetic- and metabolic pathogenesis of autism spectrum disorders by utilization of a pilot interaction modeling approach. *Autism Res* (2017) 10(8):1424–35. doi: 10.1002/aur.1780

99. Celestino-Soper PB, Shaw CA, Sanders SJ, Li J, Murtha MT, Ercan-Sencicek AG, et al. Use of array CGH to detect exonic copy number variants throughout the genome in autism families detects a novel deletion in TMLHE. *Hum Mol Genet* (2011) 20(22):4360–70. doi: 10.1093/hmg/ddr363

100. Nava C, Lamari F, Héron D, Mignot C, Rastetter A, Keren B, et al. Analysis of the chromosome X exome in patients with autism spectrum disorders identified novel candidate genes, including TMLHE. *Transl Psychiatry* (2012) 2:e179. doi: 10.1038/tp.2012.102

101. Bauman M, Kemper TL. Histoanatomic observations of the brain in early infantile autism. *Neurology* (1985) 35:866–74. doi: 10.1212/WNL.35.6.866

102. Courchesne E, Saitoh O, Yeung-Courchesne R, Press GA, Lincoln AJ, Haas RH, et al. Abnormality of cerebellar vermian lobules VI and VII in patients with infantile autism: identification of hypoplastic and hyperplastic subgroups with MR imaging. *AJR Am J Roentgenol* (1994) 162:123–30. doi: 10.2214/ajr.162.1.8273650

103. Bauman ML, Kemper TL, Arin DM. Pervasive neuroanatomic abnormalities of the brain in three cases of Rett's syndrome. *Neurology* (1995) 45:1581–6. doi: 10.1212/WNL.45.8.1581

104. Allen G, Courchesne E. Differential effects of developmental cerebellar abnormality on cognitive and motor functions in the cerebellum: an fMRI study of autism. *Am J Psychiatry* (2003) 160:262–73. doi: 10.1176/appi. ajp.160.2.262

105. Fatemi SH, Aldinger KA, Ashwood P, Bauman ML, Blaha CD, Blatt GJ, et al. Consensus paper: pathological role of the cerebellum in autism. *Cerebellum* (2012) 11:777–807. doi: 10.1007/s12311-012-0355-9

106. Riva D, Annunziata S, Contarino V, Erbetta A, Aquino D, Bulgheroni S. Gray matter reduction in the vermis and CRUS-II is associated with social and interaction deficits in low-functioning children with autistic spectrum disorders: a VBM-DARTEL Study. *Cerebellum* (2013) 12(5):676–85. doi: 10.1007/s12311-013-0469-8

107. Wang SSH, Kloth AD, Badura A. The cerebellum, sensitive periods, and autism. *Neuron* (2014) 83(3):518–32. doi: 10.1016/j.neuron.2014.07.016

108. Sundberg M, Sahin M. Cerebellar development and autism spectrum disorder in tuberous sclerosis complex. *J Child Neurol* (2015) 30(14):1954–62. doi: 10.1177/0883073815600870

109. Kim KC, Gonzales EL, Lázaro MT, Choi CS, Bahn GH, Yoo HJ, et al. Clinical and neurobiological relevance of current animal models of autism spectrum disorders. *Biomol Ther (Seoul)* (2016) 24(3):207–43. doi: 10.4062/biomolther.2016.061

110. Sundberg M, Tochitsky I, Buchholz DE, Winden K, Kujala V, Kapur K, et al. Purkinje cells derived from TSC patients display hypoexcitability and synaptic deficits associated with reduced FMRP levels and reversed by rapamycin. *Mol Psychiatry* (2018) 23(11):2167–83. doi: 10.1038/s41380-018-0018-4

111. Carter AR, Berry EM, Segal RA. Regional expression of p75NTR contributes to neurotrophin regulation of cerebellar patterning. *Mol Cell Neurosci* (2003) 22(1):1–13. doi: 10.1016/S1044-7431(02)00015-5

112. Rahimi Balaei M, Jiao X, Ashtari N, Afsharinezhad P, Ghavami S, Marzban H. Cerebellar expression of the neurotrophin receptor p75 in naked-ataxia mutant mouse. *Int J Mol Sci* (2016) 17(1):E115. doi: 10.3390/ijms17010115

113. Marzban H, Chung S, Watanabe M, Hawkes R. Phospholipase Cbeta4 expression reveals the continuity of cerebellar topography through development. *J Comp Neurol* (2007) 502(5):857–71. doi: 10.1002/cne.21352

114. Brochu G, Maler L, Hawkes R. Zebrin II: a polypeptide antigen expressed selectively by Purkinje cells reveals compartments in rat and fish cerebellum. *J Comp Neurol* (1990) 291(4):538–52. doi: 10.1002/cne.902910405

115. Armstrong CL, Krueger-Naug AM, Currie RW, Hawkes R. Constitutive expression of the 25-kDa heat shock protein Hsp25 reveals novel parasagittal bands of Purkinje cells in the adult mouse cerebellar cortex. *J Comp Neurol* (2000) 416(3):383–97. doi: 10.1002/(SICI)1096-9861(20000117)416:3<383::AID-CNE9>3.0.CO;2-M

116. Sillitoe RV, Chung SH, Fritschy JM, Hoy M, Hawkes R. Golgi cell dendrites are restricted by Purkinje cell stripe boundaries in the adult mouse cerebellar cortex. *J Neurosci* (2008a) 28(11):2820–6. doi: 10.1523/JNEUROSCI.4145-07.2008

117. Sillitoe RV, Gopal N, Joyner AL. Embryonic origins of ZebrinII parasagittal stripes and establishment of topographic Purkinje cell projections. *Neuroscience* (2008b) 162(3):574–88. doi: 10.1016/j.neuroscience.2008.12.025

118. Sillitoe RV, Stephen D, Lao Z, Joyner AL. Engrailed homeobox genes determine the organization of Purkinje cell sagittal stripe gene expression in the adult cerebellum. *J Neurosci* (2008c) 28(47):12150–62. doi: 10.1523/JNEUROSCI.2059-08.2008

119. Sgaier SK, Lao Z, Villanueva MP, Berenshteyn F, Stephen D, Turnbull RK, et al. Genetic subdivision of the tectum and cerebellum into functionally related regions based on differential sensitivity to Engrailed proteins. *Development* (2007) 134:2325–35. doi: 10.1242/dev.000620

120. White JJ, Sillitoe RV. Development of the cerebellum: from gene expression patterns to circuit maps. *Wiley Interdiscip Rev Dev Biol* (20122013) 2(1):149–64. doi: 10.1002/wdev.65

121. Sugihara I. Crus I in the rodent cerebellum: its homology to Crus I and II in the primate cerebellum and its anatomical uniqueness among neighboring lobules. *Cerebellum* (2018) 17(1):49–55. doi: 10.1007/s12311-017-0911-4

122. Dikic I, Giordano S. Negative receptor signalling. *Curr Opin Cell Biol* (2003) 15(2):128–35. doi: 10.1016/S0955-0674(03)00004-8

123. Guy GR, Jackson RA, Yusoff P, Chow SY. Sprouty proteins: modified modulators, matchmakers or missing links? *J Endocrinol* (2009) 203:191–202. doi: 10.1677/JOE-09-0110

124. Yu T, Yaguchi Y, Echevarria D, Martinez S, Basson MA. Sprouty genes prevent excessive FGF signalling in multiple cell types throughout development of the cerebellum. *Development* (2011) 138(14):2957–68. doi: 10.1242/dev.063784

125. Du W, Du W, Yu H. The role of fibroblast growth factors in tooth development and incisor renewal. *Stem Cells Int* (2018) 2018:14. doi: 10.1155/2018/7549160

126. Schwartz PM, Borghesani PR, Levy RL, Pomeroy SL, Segal RA. Abnormal cerebellar development and foliation in BDNF-/- mice reveals a role for neurotrophins in CNS patterning. *Neuron* (1997) 19(2):269–81. doi: 10.1016/S0896-6273(00)80938-1

127. Bosman LW, Hartmann J, Barski JJ, Lepier A, Noll-Hussong M, Reichardt LF, et al. Requirement of TrkB for synapse elimination in developing cerebellar Purkinje cells. *Brain Cell Biol* (2006) 35:87–101. doi: 10.1007/s11068-006-9002-z

128. Lotta LT, Conrad K, Cory-Slechta D, Schor NF. Cerebellar Purkinje cell p75 neurotrophin receptor and autistic behavior. *Transl Psychiatry* (2014) 4:e416. doi: 10.1038/tp.2014.55

129. Choo M, Miyazaki T, Yamazaki M, Kawamura M, Nakazawa T, Zhang J, et al. Retrograde BDNF to TrkB signaling promotes synapse elimination in the developing cerebellum. *Nat Commun* (2017) 8(1):195. doi: 10.1038/s41467-017-00260-w

130. Cheng I, Jin L, Rose LC, Deppmann CD. Temporally restricted death and the role of p75NTR as a survival receptor in the developing sensory nervous system. *Dev Neurobiol* (2018) 78(7):701–17. doi: 10.1002/dneu.22591

131. Segura M, Pedreño C, Obiols J, Taurines R, Pàmias M, Grünblatt E, et al. Neurotrophin blood-based gene expression and social cognition analysis in patients with autism spectrum disorder. *Neurogenetics* (2015) 16(2):123–31. doi: 10.1007/s10048-014-0434-9

132. Ohja K, Gozal E, Fahnestock M, Cai L, Cai J, Freedman JH, et al. Neuroimmunologic and neurotrophic interactions in autism spectrum disorders: relationship to neuroinflammation. *Neuromolecular Med* (2018) 20(2):161–73. doi: 10.1007/s12017-018-8488-8

133. Florez-McClure ML, Linseman DA, Chu CT, Barker PA, Bouchard RJ, Le S, et al. The p75 neurotrophin receptor can induce autophagy and death of cerebellar Purkinje neurons. *J Neurosci* (2004) 24(19):4498–509. doi: 10.1523/JNEUROSCI.5744-03.2004

134. Volosin M, Song W, Almeida RD, Kaplan DR, Hempstead BL, Friedman WJ. Interaction of survival and death signaling in basal forebrain neurons: roles of neurotrophins and proneurotrophins. *J Neurosci* (2006) 26(29):7756–66. doi: 10.1523/JNEUROSCI.1560-06.2006

135. Song W, Volosin M, Cragnolini AB, Hempstead BL, Friedman WJ. ProNGF induces PTEN via p75NTR to suppress Trk-mediated survival signaling in brain neurons. *J Neurosci* (2010) 30(46):15608–15. doi: 10.1523/JNEUROSCI.2581-10.2010

136. Vicario A, Kisiswa L, Tann JY, Kelly CE, Ibáñez CF. Neuron-type-specific signaling by the p75NTR death receptor is regulated by differential proteolytic cleavage. *J Cell Sci* (2015) 128(8):1507–17. doi: 10.1242/jcs.161745

137. Pathak A, Carter BD. Retrograde apoptotic signaling by the p75 neurotrophin receptor. *Neuronal Signal* (2017) 1:NS20160007. doi: 10.1042/NS20160007

138. Kisiswa L, Fernández-Suárez D, Sergaki MC, Ibáñez CF. RIP2 gates TRAF6 interaction with death receptor p75NTR to regulate cerebellar granule neuron survival. *Cell Rep* (2018) 24(4):1013–24. doi: 10.1016/j.celrep.2018.06.098

139. Chen Y, Zeng J, Cen L, Chen Y, Wang X, Yao G, et al. Multiple roles of the p75 neurotrophin receptor in the nervous system. *J Int Med Res* (2009) 37(2):281–8. Review. Erratum in: J Int Med Res. 2009 May-Jun;37(3):974. Cen, L [added]. doi: 10.1177/147323000903700201

140. Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA. Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. *Cell* (1998) 92:253–63. doi: 10.1016/S0092-8674(00)80919-8

141. Walker DJ, Land SC. Regulation of vascular signalling by nuclear Sprouty2 in fetal lung epithelial cells: implications for co-ordinated airway and vascular branching in lung development. *Comp Biochem Physiol B Biochem Mol Biol* (2018) 224:105–14. doi: 10.1016/j.cbpb.2018.01.007

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.